Zacks Research Brokers Raise Earnings Estimates for Omnicell

Omnicell, Inc. (NASDAQ:OMCL) – Research analysts at Zacks Research lifted their Q4 2024 EPS estimates for shares of Omnicell in a research note issued on Thursday, January 2nd. Zacks Research analyst R. Department now expects that the company will post earnings of $0.29 per share for the quarter, up from their prior estimate of $0.28. The consensus estimate for Omnicell’s current full-year earnings is $0.93 per share. Zacks Research also issued estimates for Omnicell’s Q1 2025 earnings at $0.16 EPS, Q2 2025 earnings at $0.19 EPS and FY2026 earnings at $1.01 EPS.

Other research analysts have also recently issued research reports about the stock. Benchmark restated a “buy” rating and set a $48.00 target price on shares of Omnicell in a research note on Wednesday, October 9th. Bank of America reiterated a “neutral” rating and issued a $57.00 price target (up previously from $44.00) on shares of Omnicell in a research note on Thursday, October 31st. Craig Hallum boosted their price target on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Wells Fargo & Company boosted their price target on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research note on Monday, October 14th. Finally, JPMorgan Chase & Co. upped their price target on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Five analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $52.00.

Omnicell Stock Performance

OMCL opened at $45.32 on Monday. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $55.74. The firm’s fifty day moving average is $46.17 and its 200 day moving average is $40.56. The stock has a market cap of $2.10 billion, a price-to-earnings ratio of -116.20, a price-to-earnings-growth ratio of 34.96 and a beta of 0.78.

Institutional Investors Weigh In On Omnicell

Hedge funds and other institutional investors have recently bought and sold shares of the company. Rhumbline Advisers increased its stake in shares of Omnicell by 3.0% in the second quarter. Rhumbline Advisers now owns 147,188 shares of the company’s stock worth $3,984,000 after acquiring an additional 4,281 shares during the period. Arizona State Retirement System grew its position in Omnicell by 2.9% during the second quarter. Arizona State Retirement System now owns 12,853 shares of the company’s stock valued at $348,000 after buying an additional 357 shares during the period. Headlands Technologies LLC acquired a new stake in Omnicell during the second quarter valued at $104,000. Federated Hermes Inc. grew its position in Omnicell by 1,113.6% during the second quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock valued at $26,830,000 after buying an additional 909,480 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in Omnicell by 0.3% during the second quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock valued at $31,955,000 after buying an additional 3,570 shares during the period. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Insiders Place Their Bets

In related news, Director Mark W. Parrish sold 12,000 shares of the stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the sale, the director now owns 58,427 shares of the company’s stock, valued at $2,763,597.10. This represents a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 2.64% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.